US News

Analysis – Pfizer/BioNTech bid for booster doses premature, more data needed – experts

Published by

By Julie Steenhuysen and Michael Erman CHICAGO (Reuters) – Pfizer Inc’s push for health regulators to authorize a third dose of its COVID-19 shot is not yet backed by evidence, despite the fast-spreading Delta variant, vaccine experts said. Pfizer and German partner BioNTech SE said last week that they will ask U.S. and European regulators within weeks to authorize a booster dose due to an increased risk of infection after six months. The companies did not share the data showing that risk, but said it would soon be made public. A meeting with federal health officials to discuss the matter was …

Read More

Facebook Comments

Check Also

“Party On Garth!” – Market Rally Continues As Earnings Beat Estimates

“Party On Garth!” – Market Rally Continues As ...